FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.
Cytophage Technologies (TSXV: CYTO) has officially launched trials with a poultry hatcheries in Canada. The trial will see Cytophage’s OvaPhage product used to target harmful bacteria on the surface of eggs.
OvaPhage, a product under Cytophage’s Farm Phage line of products in its Animal Health Division, has been designed as a bacteriophage product that targets harmful bacteria that exists on the surface of eggs while preserving the natural protective layer on eggs. Early lab tests have seen a 99% reduction in bacterial load on the surface of an egg when OvaPhage is used.
Sponsored · Selkirk Copper Mines
The current trials are slated to be completed by the end of Q3 of this year, after which Cytophage intends to prepare regulatory submissions. Those submissions are then to clear a path for the initial market launch of OvaPhage into the Canadian market, which is anticipated to be followed by a global expansion.
“This moment marks a turning point for our company. Moving from the lab to incubator egg trials is a key milestone in proving OvaPhage’s real-world efficacy. We are excited to demonstrate how this technology can redefine standards for the industry,” commented Dr. Steven Theriault, CEO of Cytophage.
READ: Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba
Canada is currently home to over 200 hatching egg producers, who in 2023 produced an estimated 868 million broiler hatching eggs, leading to $500 million in farm revenues. The partner within the OvaPhage trial is said to represent a key segment of this market, and is a leader in advanced poultry management systems.
Cytophage Technologies last traded at $0.225 on the TSX Venture.
FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
